Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: GlobeNewswire
IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares were offered by Tarsus. The aggregate gross proceeds to Tarsus from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $101.2 million. The shares began trading on The Nasdaq Global Select Market on October 16, 2020 under the symbol “TARS.” BofA Securities, Jefferies and Raymond James acted as joint book-running managers for the offering. LifeSci
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon [Yahoo! Finance]Yahoo! Finance
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonGlobeNewswire
- Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14% [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name [Seeking Alpha]Seeking Alpha
TARS
Earnings
- 2/27/24 - Beat
TARS
Sec Filings
- 4/23/24 - Form 8-K
- 4/11/24 - Form 144
- 3/28/24 - Form 144
- TARS's page on the SEC website